Podcast

Making Headway in GI Malignancies in Miami

Author(s):

OncLive Staff

We recently traveled to Miami, Florida for a State of the Science Summit™ on Gastrointestinal Malignancies, which featured insights from Florida Society of Clinical Oncology faculty.

We recently traveled to Miami, Florida for a State of the Science Summit™ on Gastrointestinal Malignancies. At the meeting, faculty from the Florida Society of Clinical Oncology discussed the novel agents that are generating excitement in advanced hepatocellular carcinoma and cholangiocarcinoma and the novel therapies and strategies that are propelling progress in gastric cancer.

Moreover, panelists shed light on the use of molecular testing in colorectal cancer and the current and investigational treatment strategies in the relapsed/refractory setting. Other key topics included remaining challenges with staging in pancreatic cancer, unanswered questions in the localized setting, and the benefits of olaparib in the metastatic setting.

Interested in attending an upcoming OncLive® State of the Science Summit™ in your area? Register today.

Related Videos
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.
Tanios Bekaii-Saab, MD, FACP
Michel Ducreux, MD, PhD, head, Gastrointestinal Oncology Unit, head, Gastrointestinal Oncology Tumor Board, Gustave Roussy; professor, oncology, Paris-Saclay University
Piotr Rutkowski, MD
Yelena Y. Janjigian, MD
Zhi Peng, MD
Related Content
Nataliya Uboha, MD, PhD, of Wisconsin School of Medicine
October 28th 2024

The Debate Over the Predictive Utility of PD-L1–Low Expression is Ongoing in ESCC

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
October 30th 2024

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

Nataliya Uboha, MD, PhD
October 25th 2024

ODAC Votes on PD-1 Inhibitors Underscore Importance of Biomarker Testing in Gastric/GEJ and Esophageal Cancers

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
October 24th 2024

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD

Professor Florian Lordick, MD, PhD, director, professor, Oncology, University Cancer Center
October 21st 2024

Frontline Tislelizumab/Chemo Approaches EU Approval for Gastric/GEJ Adenocarcinoma and ESCC

The OncFive
October 19th 2024

The OncFive: Top Oncology News and Trends for the Week of 10/13